​

MoonLake Immunotherapeutics (MLTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MLTX Stock Forecast

MoonLake Immunotherapeutics (MLTX) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $15.00, with a high of $25.00 and a low of $7.00. This represents a 48.96% increase from the last price of $10.07.

$5 $17 $29 $41 $53 $65 High: $25 Avg: $15 Low: $7 Last Closed Price: $10.07

MLTX Stock Rating

MoonLake Immunotherapeutics stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (66.67%), 5 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 15 5 10 0 Strong Sell Sell Hold Buy Strong Buy

MLTX Price Target Upside V Benchmarks

TypeNameUpside
StockMoonLake Immunotherapeutics48.96%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts667
Avg Price Target$15.00$15.00$22.43
Last Closing Price$10.07$10.07$10.07
Upside/Downside48.96%48.96%122.74%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 252951-17
Sep, 253131--17
Aug, 254121--17
Jul, 25412---16
Jun, 25412---16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 07, 2025Oppenheimer$25.00$8.66188.68%148.26%
Sep 30, 2025Goldman Sachs$7.00$7.17-2.37%-30.49%
Sep 30, 2025Serge BelangerNeedham$20.00$6.25220.00%98.61%
Sep 30, 2025Guggenheim$20.00$6.25220.00%98.61%
Sep 29, 2025Jefferies$8.00$6.0232.89%-20.56%
Sep 29, 2025RBC Capital$10.00$6.9643.68%-0.70%
Mar 18, 2025RBC Capital$67.00$40.8564.01%565.34%
Jul 01, 2024Raghuram SelvarajuH.C. Wainwright$100.00$43.97127.43%893.05%
Apr 02, 2024Richard LawGoldman Sachs$62.00$48.6027.57%515.69%
Aug 31, 2023Serge BelangerNeedham$76.00$56.1035.47%654.72%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 02, 2025H.C. WainwrightBuyNeutraldowngrade
Sep 30, 2025Goldman SachsNeutralMixeddowngrade
Sep 30, 2025NeedhamBuyBuyhold
Sep 30, 2025CitigroupBuyNeutraldowngrade
Sep 29, 2025JefferiesBuyHolddowngrade
Sep 29, 2025BTIGBuyNeutraldowngrade
Sep 29, 2025RBC CapitalSector Performdowngrade
Jun 03, 2025CitigroupBuyBuyhold
May 19, 2025Wolfe ResearchPeer PerformOutperformupgrade
Jan 09, 2025BTIGBuyBuyhold

Financial Forecast

EPS Forecast

$-2K $-2K $-1K $-500 $0 $500 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.73$-1.92K----
Avg Forecast$-0.90$-1.79$-2.77$-3.33$-3.63$0.80
High Forecast$-0.84$-1.61$-2.00$-2.09$-1.92$0.80
Low Forecast$-0.93$-1.92$-3.39$-4.31$-5.97$0.80
Surprise %-18.89%107135.20%----

Revenue Forecast

$100M $210M $320M $430M $540M $650M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast----$115.80M$645.41M
High Forecast----$120.20M$645.41M
Low Forecast----$111.40M$645.41M
Surprise %------

Net Income Forecast

$-150B $-110B $-70B $-30B $10B $50B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-36.01M$-120.68B----
Avg Forecast$-43.46M$-80.77M$-132.53M$-157.26M$-267.54M$39.13M
High Forecast$-41.39M$-79.04M$-98.31M$-102.62M$-94.19M$39.13M
Low Forecast$-45.53M$-94.16M$-166.76M$-211.90M$-293.19M$39.13M
Surprise %-17.15%149315.46%----

MLTX Forecast FAQ

Is MoonLake Immunotherapeutics stock a buy?

MoonLake Immunotherapeutics stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that MoonLake Immunotherapeutics is a favorable investment for most analysts.

What is MoonLake Immunotherapeutics's price target?

MoonLake Immunotherapeutics's price target, set by 15 Wall Street analysts, averages $15 over the next 12 months. The price target range spans from $7 at the low end to $25 at the high end, suggesting a potential 48.96% change from the previous closing price of $10.07.

How does MoonLake Immunotherapeutics stock forecast compare to its benchmarks?

MoonLake Immunotherapeutics's stock forecast shows a 48.96% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for MoonLake Immunotherapeutics over the past three months?

  • October 2025: 11.76% Strong Buy, 52.94% Buy, 29.41% Hold, 5.88% Sell, 0% Strong Sell.
  • September 2025: 17.65% Strong Buy, 76.47% Buy, 5.88% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 23.53% Strong Buy, 70.59% Buy, 5.88% Hold, 0% Sell, 0% Strong Sell.

What is MoonLake Immunotherapeutics’s EPS forecast?

MoonLake Immunotherapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.77, marking a -99.86% decrease from the reported $-1.92K in 2024. Estimates for the following years are $-3.33 in 2026, $-3.63 in 2027, and $0.8 in 2028.

What is MoonLake Immunotherapeutics’s revenue forecast?

MoonLake Immunotherapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, followed by $115.8M for 2027, and $645.41M for 2028.

What is MoonLake Immunotherapeutics’s net income forecast?

MoonLake Immunotherapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-133M, representing a -99.89% decrease from the reported $-121B in 2024. Projections indicate $-157M in 2026, $-268M in 2027, and $39.13M in 2028.